SOMNF (SomnoMed) ROCE %: 8.74% (As of Dec. 2025)


SOMNF SomnoMed Ltd SOMNF
49 GF Score
Price $0.45
GF Value $0.33
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is SomnoMed ROCE %?

SomnoMed SOMNF 49 ROCE % is 8.74% as of Dec. 2025. GuruFocus rates SOMNF with a GF Score™ of 49/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SomnoMed's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.74%.

SomnoMed  (OTCPK:SOMNF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SomnoMed ROCE % Related Terms

SomnoMed ROCE % Historical Data

* Premium members only.

The historical data trend for SomnoMed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed ROCE % Chart

SomnoMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.48 -9.19 -12.19 -16.79 -1.30

SomnoMed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.52 -17.32 6.04 -9.05 8.74
SOMNF
49GF Score
SomnoMed Ltd SOMNF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SomnoMed ROCE % Calculation

SomnoMed's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-0.452/( ( (50.525 - 14.906) + (52.715 - 18.605) )/ 2 )
=-0.452/( (35.619+34.11)/ 2 )
=-0.452/34.8645
=-1.30 %

SomnoMed's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=3.088/( ( (52.715 - 18.605) + (53.089 - 16.519) )/ 2 )
=3.088/( ( 34.11 + 36.57 )/ 2 )
=3.088/35.34
=8.74 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.74% mean?
SomnoMed (SOMNF) has a ROCE % of 8.74% as of Dec. 2025.
Is SomnoMed's ROCE % too high?
SomnoMed's current ROCE % is 8.74%. The Medical Devices & Instruments industry median ROCE % is 2.20. SomnoMed's value of 8.74% is 297.3% above this industry median. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's ROCE % compare to ABT and SYK?
SomnoMed's ROCE % of 8.74% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. SomnoMed's value of 8.74% is 297.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SomnoMed's current ROCE % of 8.74% is 297.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current ROCE % is 8.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (SOMNF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $0.45 — trading 35.7% above its estimated fair value. The current ROCE % is 8.74% and 297.3% above the Medical Devices & Instruments industry median of 2.20. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SomnoMed (SOMNF), the current ROCE % is 8.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (SOMNF) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of $0.45 is trading 35.7% above its estimated GF Value™ of $0.33. GuruFocus considers SomnoMed to be Significantly Overvalued.

Key valuation signals for SOMNF:

  • ROCE %: 8.74%
  • GF Value™: $0.33 vs. price of $0.45 (35.7% above fair value)
  • GF Score™: 49/100 with 3 warning signs
  • Industry Position: 297.3% above the Medical Devices & Instruments median

No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges RJV:GermanySOM:Australia
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for SOMNF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$0.33
GF Value